S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
S&P 500   3,132.52 (-0.11%)
DOW   27,881.72 (-0.10%)
QQQ   203.90 (-0.08%)
AAPL   268.48 (+0.58%)
FB   200.87 (-0.23%)
MSFT   151.13 (-0.15%)
GOOGL   1,342.89 (+-0.01%)
AMZN   1,739.21 (-0.59%)
CGC   20.09 (-5.64%)
NVDA   213.98 (+0.85%)
MU   47.46 (+2.17%)
BABA   200.45 (+0.86%)
GE   11.01 (+0.18%)
TSLA   348.84 (+2.74%)
T   38.06 (+0.05%)
AMD   39.44 (+1.31%)
ACB   2.52 (-3.82%)
F   9.07 (+0.67%)
PRI   135.27 (-0.06%)
NFLX   293.12 (-3.10%)
BAC   33.53 (+0.06%)
GILD   67.08 (+0.22%)
DIS   146.10 (-0.08%)
Log in

NASDAQ:MRNS - Marinus Pharmaceuticals Stock Price, Forecast & News

$1.29
+0.02 (+1.57 %)
(As of 12/10/2019 04:00 PM ET)
Today's Range
$1.24
Now: $1.29
$1.32
50-Day Range
$1.03
MA: $1.19
$1.33
52-Week Range
$0.77
Now: $1.29
$5.40
Volume422,718 shs
Average Volume940,029 shs
Market Capitalization$69.49 million
P/E RatioN/A
Dividend YieldN/A
Beta2.87
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three dose forms, including intravenous (IV), oral capsule, and oral liquid for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRNS
CUSIPN/A
Phone484-801-4670

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.30 per share

Profitability

Net Income$-36,730,000.00

Miscellaneous

Employees28
Market Cap$69.49 million
Next Earnings Date3/9/2020 (Estimated)
OptionableOptionable

Receive MRNS News and Ratings via Email

Sign-up to receive the latest news and ratings for MRNS and its competitors with MarketBeat's FREE daily newsletter.


Marinus Pharmaceuticals (NASDAQ:MRNS) Frequently Asked Questions

What is Marinus Pharmaceuticals' stock symbol?

Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals Inc (NASDAQ:MRNS) posted its quarterly earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.02. View Marinus Pharmaceuticals' Earnings History.

When is Marinus Pharmaceuticals' next earnings date?

Marinus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Marinus Pharmaceuticals.

What price target have analysts set for MRNS?

7 brokerages have issued 12-month price objectives for Marinus Pharmaceuticals' stock. Their forecasts range from $1.70 to $29.00. On average, they expect Marinus Pharmaceuticals' stock price to reach $9.67 in the next year. This suggests a possible upside of 649.7% from the stock's current price. View Analyst Price Targets for Marinus Pharmaceuticals.

What is the consensus analysts' recommendation for Marinus Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Marinus Pharmaceuticals.

What are Wall Street analysts saying about Marinus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Marinus Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures. Marinus Pharmaceuticals, Inc. is headquartered in New Haven, Connecticut. " (11/12/2019)
  • 2. LADENBURG THALM/SH SH analysts commented, "We find this is the right and not completely unexpected decision considering his enthusiasm in developing ganaxolone, his broad experience in companies and as an investor, as well as the need for strong stewardship at this time." (8/9/2019)
  • 3. Cantor Fitzgerald analysts commented, "Given the compelling Phase 2 data announced in CDD, market size potential in PPD (with positive interim data reported in 4Q18), and undervaluation relative to peers, we believe Marinus shares offer a compelling risk-reward profile. Valuation Summary We arrive at our 12-month PT of $22/share by assessing the after-tax, risk-adjusted NPV of potential future cash flows from ganaxolone for the treatment of postpartum depression and CDKL5 deficiency disorder." (5/1/2019)

Has Marinus Pharmaceuticals been receiving favorable news coverage?

News stories about MRNS stock have trended somewhat positive on Tuesday, InfoTrie reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Marinus Pharmaceuticals earned a media sentiment score of 1.3 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Marinus Pharmaceuticals.

Are investors shorting Marinus Pharmaceuticals?

Marinus Pharmaceuticals saw a decrease in short interest in November. As of November 15th, there was short interest totalling 2,950,000 shares, a decrease of 11.1% from the October 31st total of 3,320,000 shares. Based on an average daily trading volume, of 1,370,000 shares, the short-interest ratio is currently 2.2 days. Currently, 6.3% of the company's shares are short sold. View Marinus Pharmaceuticals' Current Options Chain.

Who are some of Marinus Pharmaceuticals' key competitors?

What other stocks do shareholders of Marinus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Marinus Pharmaceuticals investors own include Nordic American Tanker (NAT), The Gabelli Dividend & Income Trust (GDV), Realty Income (O), Novavax (NVAX), Micron Technology (MU), TG Therapeutics (TGTX), Verastem (VSTM), XOMA (XOMA), Viking Therapeutics (VKTX) and Alibaba Group (BABA).

Who are Marinus Pharmaceuticals' key executives?

Marinus Pharmaceuticals' management team includes the folowing people:
  • Mr. Edward F. Smith, VP, CFO, Treasurer & Sec. (Age 48)
  • Mr. Christopher Michael Cashman, CEO, Pres & Director (Age 62)
  • Dr. Lorianne K. Masuoka, Chief Medical Officer (Age 58)
  • Dr. Scott Braunstein, Exec. Chairman (Age 56)
  • Ms. Lisa M. Caperelli, Exec. Director of Investor & Strategic Relations

Who are Marinus Pharmaceuticals' major shareholders?

Marinus Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (1.73%), Barclays PLC (0.11%) and Bluefin Trading LLC (0.03%). Company insiders that own Marinus Pharmaceuticals stock include Bain Capital Life Sciences Inv, Christopher Michael Cashman and Edward F Smith. View Institutional Ownership Trends for Marinus Pharmaceuticals.

Which institutional investors are selling Marinus Pharmaceuticals stock?

MRNS stock was sold by a variety of institutional investors in the last quarter, including Bluefin Trading LLC. Company insiders that have sold Marinus Pharmaceuticals company stock in the last year include Christopher Michael Cashman and Edward F Smith. View Insider Buying and Selling for Marinus Pharmaceuticals.

Which institutional investors are buying Marinus Pharmaceuticals stock?

MRNS stock was bought by a variety of institutional investors in the last quarter, including State Street Corp and Barclays PLC. View Insider Buying and Selling for Marinus Pharmaceuticals.

How do I buy shares of Marinus Pharmaceuticals?

Shares of MRNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Marinus Pharmaceuticals' stock price today?

One share of MRNS stock can currently be purchased for approximately $1.29.

How big of a company is Marinus Pharmaceuticals?

Marinus Pharmaceuticals has a market capitalization of $69.49 million. The biopharmaceutical company earns $-36,730,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Marinus Pharmaceuticals employs 28 workers across the globe.View Additional Information About Marinus Pharmaceuticals.

What is Marinus Pharmaceuticals' official website?

The official website for Marinus Pharmaceuticals is http://www.marinuspharma.com/.

How can I contact Marinus Pharmaceuticals?

Marinus Pharmaceuticals' mailing address is 100 Matsonford Rd Suite 100, Radnor PA, 19087. The biopharmaceutical company can be reached via phone at 484-801-4670 or via email at [email protected]


MarketBeat Community Rating for Marinus Pharmaceuticals (NASDAQ MRNS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  322 (Vote Outperform)
Underperform Votes:  259 (Vote Underperform)
Total Votes:  581
MarketBeat's community ratings are surveys of what our community members think about Marinus Pharmaceuticals and other stocks. Vote "Outperform" if you believe MRNS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRNS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Featured Article: Outperform Rating

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel